BackPOINT Biopharma Global Overview

POINT Biopharma Global Operating Income

Latest operating income for PNT: $110M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-29626162.00
↑ 20.25% YoY

As of Sep 30, 2023

Annual Operating Income (TTM)

$107.77M

Trailing 12 months ending Sep 30, 2023

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

POINT Biopharma Global (PNT) FAQ

As of the most recent data (September 2023), PNT shows a operating income of $110M. Scroll down for historical charts and peer comparison views.

Tracking PNT's operating income over time shows whether POINT Biopharma Global is scaling, shrinking, or reshaping that part of the business. The current reading is $110M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has POINT Biopharma Global's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $110M) with ownership activity and broader fundamentals.

POINT Biopharma Global's operating income is $110M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.